Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456696 | 0.86 | HTR2C (0.38) | HTR2C | |
| SCHEMBL3863432 | 0.81 | ESR2 (0.36) | ESR2HTR2COPRL1 | |
| SCHEMBL3773179 | 0.81 | ESR1 (0.41) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1815764 | 0.78 | HTR2C (0.58) | HTR2C | |
| SCHEMBL28694986 | 0.76 | HTR2C (0.59) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL18640064 | 0.76 | HTR2C (0.59) | ESR1ESR2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1810814 | 0.76 | SLC18A3 (0.48) | OPRL1 | |
| SCHEMBL3762171 | 0.74 | ESR2 (0.44) | ESR2HTR2C | |
| SCHEMBL458052 | 0.73 | HTR2C (0.39) | HTR2C | |
| SCHEMBL3775718 | 0.71 | HTR2C (0.31) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | ESR1 1868/4885ESR2 1107/4885CYP3A4 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.